Echocardiographic Evaluation of Left Ventricular Hyper

Journal of Cardiovascular Pharmacology 8, S61-S68

DOI: 10.1097/00005344-198608003-00014

Citation Report

#	Article	IF	CITATIONS
1	Echocardiographic Detection of Left Ventricular Hypertrophy. Chest, 1987, 92, 923-925.	0.8	5
2	Cardiovascular outcomes of treating high blood pressure. American Heart Journal, 1987, 114, 965-971.	2.7	6
3	Whole-day blood pressure Hypertension, 1988, 11, 288-298.	2.7	34
4	Comparison of Antihypertensive Therapies by Noninvasive Techniques. Chest, 1989, 96, 74-79.	0.8	26
5	Hypertension in the aged: A pathophysiologic basis for treatment. American Journal of Cardiology, 1989, 63, 25-32.	1.6	74
6	New insights and new approaches for the treatment of essential hypertension: Selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. American Heart Journal, 1989, 117, 911-951.	2.7	112
7	The Use of Alpha1 Adrenergic Blocking Agents for Hypertension. American Pharmacy, 1990, 30, 54-63.	0.2	1
8	Optimizing cardiovascular risk reduction during antihypertensive therapy Hypertension, 1990, 16, 201-211.	2.7	9
9	Hypertension with concomitant conditions: The changing role of $\hat{l}^2$ -adrenoceptor blockade. American Heart Journal, 1991, 121, 716-723.	2.7	14
10	Cardiovascular and metabolic characteristics of hypertension. American Journal of Medicine, 1991, 91, S4-S10.	1.5	20
11	Alpha <sub>1</sub> blockers. Postgraduate Medicine, 1991, 89, 89-112.	2.0	4
12	Left ventricular diastolic filling alterations in normotensive young adults with a family history of systemic hypertension. American Journal of Cardiology, 1991, 68, 51-56.	1.6	61
13	Endurance Exercise Training and Treatment of Hypertension. Sports Medicine, 1992, 13, 71-77.	6.5	8
14	Antihypertensive therapy. Postgraduate Medicine, 1992, 91, 163-193.	2.0	7
15	Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition. American Heart Journal, 1992, 123, 1414-1420.	2.7	28
16	Clinical Applications of Alpha <sub>1</sub> â€Receptor Blockade: Terazosin in the Management of Hypertension. Journal of Clinical Pharmacology, 1993, 33, 866-899.	2.0	2
17	Left-Ventricular Diastolic Function and Hypertension. Cardiology Clinics, 1995, 13, 559-567.	2.2	7
18	An open-label, uncontrolled trial of the angiotensin-converting enzyme inhibitor cilazapril in the treatment of patients with chronic congestive heart failure. Current Therapeutic Research, 1997, 58, 594-600.	1.2	2

#	Article	IF	CITATIONS
19	Hemodynamic and Metabolic Effects of Transdermal Clonidine in Patients With Hypertension and Non–Insulin-Dependent Diabetes Mellitus. American Journal of Hypertension, 1998, 11, 184-189.	2.0	14
20	The impact of electrocardiographic left ventricular hypertrophy and bundle branch block on the triage and outcome of ED patients with a suspected acute coronary syndrome: a multicenter study. American Journal of Emergency Medicine, 2004, 22, 156-163.	1.6	15
21	Programmed hypertension in rats treated with a NF- $\hat{1}^{\circ}$ B inhibitor during nephrogenesis: renal mechanisms. Hypertension Research, 2011, 34, 693-700.	2.7	9
22	Regression of Electrocardiographic Signs of Left Ventricular Hypertrophy by Combined Treatment With Thiazide Diuretic and Angiotensin-II Receptor Blocker. Circulation Journal, 2014, 78, 2719-2726.	1.6	4
23	Cardiovascular Risk Factor Profile of Hypertension: Therapeutic Approaches. Medical Science Symposia Series, 1992, , 133-140.	0.0	0